| Literature DB >> 25878072 |
Jens Bangsbo1, Peter Riis Hansen2, Jiri Dvorak3, Peter Krustrup4.
Abstract
Over the past 10 years, researchers have studied the effects of recreational football training as a health-promoting activity for participants across the lifespan. This has important public health implications as over 400 million people play football annually. Results from the first randomised controlled trial, published in the BJSM in January 2009, showed that football increased maximal oxygen uptake and muscle and bone mass, and lowered fat percentage and blood pressure, in untrained men, and since then more than 70 articles about football for health have been published, including publications in two supplements of the Scandinavian Journal of Medicine and Science in Sports in 2010 and 2014, prior to the FIFA World Cup tournaments in South Africa and Brazil. While studies of football training effects have also been performed in women and children, this article reviews the current evidence linking recreational football training with favourable effects in the prevention and treatment of disease in adult men. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25878072 PMCID: PMC4413738 DOI: 10.1136/bjsports-2015-094781
Source DB: PubMed Journal: Br J Sports Med ISSN: 0306-3674 Impact factor: 13.800
Figure 1Heart rate distribution, expressed as a percentage of maximum heart rate, during football training consisting of small-sided games for various study groups. Data are presented as means±SEM. HRmax, maximal heart rate.
Changes in cardiovascular variables in untrained men as a result of a period of recreational F training compared to R or inactive C
| Study | Activity, target group, gender | Age (years) | Training intervention; | VO2max (mL/kg/min or %) | VO2max (L/min or %) | HR sub-max (bpm) | HR rest (bpm) | BPsys rest, (mmHg) | BPdia rest, (mmHg) | MAP rest (mmHg) | RV systolic function, TAPSE (cm) | LV diastolic function, E/A ratio (%) | Arterial stiffness (AI) (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Krustrup | F, UT, M, | 29 | 12; 82%HRmax; 2.3; 60 | 13%↑* | 11%↑* | 20↓*† | 6↓* | 8↓* | 5↓* | 6↓* | – | – | – |
| R, UT, M | 31 | 12; 82%HRmax; 2.5; 60 | 8%↑* | 7%↑* | 21↓*† | 6↓* | 7↓* | 5↓* | 6↓* | – | – | – | |
| C, UT, M | 31 | No intervention | 1%↓NS | 1%↓NS | 0↔NS | 1↑NS | 2↓NS | 2↑NS | 1↑NS | – | – | – | |
| Randers | F, UT, M | 31 | 64; 82%HRmax; 1.3; 60 | 8%↑* | 6%↑* | 22↓*† | 8↓*‡ | 8↓*‡ | 3↓NS | 5↓* | – | – | – |
| C, UT, M | 32 | No intervention | – | – | – | 2↓NS | 2↓NS | 3↑NS | 1↑NS | – | – | – | |
| Schmidt | F, UT, M | 68 | 52; 82%HRmax; 1.7; 45–60 | – | 18%↑*‡ | – | 8↓* | NS | NS | NS | 0.5↑*‡ | 25%↑*‡ | – |
| S, UT, M | 69 | 52; 8–20RM; 1.9; 45–60 | – | 3%↑NS | – | 2↓NS | NS | NS | NS | 0.0↔NS | NS | – | |
| C, UT, M | 67 | No intervention | – | 1%↑NS | – | 2↓NS | NS | NS | NS | 0.2 ↓NS | NS | – | |
| Andersen | F, UT, M | 68 | 16; 84%HRmax; 1.6; 45–60 | 3.8↑* | – | 8↓* | – | – | – | – | – | – | – |
| S, UT, M | 69 | 16; 8–20RM; 1.5; 45–60 | 0.8↑NS | – | 9↓NS | – | – | – | – | – | – | – | |
| C, UT, M | 67 | No intervention | 0.7↓NS | 7↓NS | |||||||||
| Krustrup | F, UT, Ma, | 46 | 24; 85%HRmax; 1.7; 60 | 8%↑* | – | 12↓NS | 8↓* | 13↓*‡ | 8↓*‡ | 10↓*‡ | – | – | 7%↓* |
| DAG, UT, Ma | 47 | DA on CRF | 3%↓NS | – | 4↓NS | 3↓NS | 8↓* | 3↓* | 5↓* | – | – | ↔NS | |
| Andersen | F, UT, Ma | 46 | 24; 83%HRmax; 1.7; 60 | 8%↑* | – | – | 8↓* | – | – | 10↓*‡ | 0.4↑*‡ | 34%↑*‡ | – |
| DAG, UT, Ma | 47 | DA on CRF | 2%↓NS | – | – | 3↓NS | – | – | 5↓* | NS | NS | – | |
| Knoepfli-Lenzin | F, UT, Mmh | 37 | 12; 80%HRmax; 2.4; 60 | 9%↑* | 6%↑* | – | 7↓* | 11↓* | 9↓*‡ | 10↓*† | – | – | – |
| R, UT, Mmh | 36 | 12; 79%HRmax; 2.5; 60 | 12%↑* | 11%↑* | – | 9↓* | 7↓* | 6↓* | 6↓* | – | – | – | |
| C, UT, Mmh | 38 | No intervention | 1%↑NS | 1%↑NS | – | 6↓* | 7↓* | 4↓* | 6↓* | – | – | – | |
| Schmidt | F, UT, Mt | 51 | 24; 82%HRmax; 1.2; 60 | 12%↑* | 11%↑* | – | 6↓NS | 9↓* | 8↓* | 8↓* | 0.4↑*‡ | 18%*↑ | 0.1%↑NS |
| C, UT, Mt | 49 | No intervention | 2%↑NS | 2%↑NS | – | 2↑NS | 3↑NS | 0↔NS | 1↑NS | 0.1↓NS | NS | 0.6%↑NS | |
| De Sousa | F, UT, Mt+Wt | 61 | 12; 83%HRmax; 3; 40; F+D | 10%↑*‡ | – | – | – | – | – | – | – | – | – |
| C, UT, Mt+Wt | 61 | Diet group | 3%↓ NS | – | – | – | – | – | – | – | – | – | |
| Uth | F, UT, Mp | 67 | 12; 85%HRmax; 2–3; 45–60 | 1.5↑* | – | – | – | – | – | – | – | – | – |
| C, UT, Mp | 67 | No intervention | 0.3↑ NS | – | – | – | – | – | – | – | – | – | |
| Faude | F, UT, OCh | 11 | 12; 80%HRmax; 4.5; 60 | 7%↓NS | 5%↓NS | 7↓* | – | – | – | – | – | – | – |
| SP, UT, OCh | 11 | 12; 77%HRmax; 4.5; 60 | 7%↓NS | 3%↓NS | 7↓* | – | – | – | – | – | – | – | |
| Hansen | F, UT, OCh | 10 | 12; >80%HRmax; 4; 60–90 | – | – | – | – | – | – | – | 0.26↑*‡ | NS | 1.9%↑NS |
| C, UT, OCh | 11 | No intervention | – | – | – | – | – | – | – | NS | NS | 2.7%↓NS |
Changes between pretraining and post-training intervention (unless otherwise stated).
*Significant difference from 0 weeks.
†Significant group difference compared to control.
‡Significant group difference.
a, hypertensive participants; AI, augmentation index; BPdia, diastolic blood pressure; BPsys, systolic blood pressure; C, controls; CRF, cardiovascular risk factors; DAG, doctor's advice group; E/A ratio, ratio of early (E) to late (A) ventricular filling velocities; F, football; F+D, football + diet group; HRmax, maximal heart rate; LV left ventricular; M, men; MAP, mean arterial pressure; mh, mildly hypertensive participants; NS, not significant; OC, overweight children; p, prostate cancer patients; R, running; RV, right ventricular; S, strength training; SP, standard physical activity; t, type 2 diabetics; TAPSE, tricuspid annular plane systolic excursion; UT, untrained; W, women.
Changes in blood lipids in untrained men as a result of a period of recreational F training compared to R or inactive C
| Study | Activity, target group, gender | Age (years) | Training intervention; | Total-Chol rest (mmol/l or %) | HDL-Chol rest (mmol/l or %) | LDL-Chol rest (mmol/l or %) |
|---|---|---|---|---|---|---|
| Krustrup | F, UT, M | 29 | 12; 82%HRmax; 2.3; 60 | 5%↓NS | 8%↑NS | 15%↓*† |
| R, UT, M | 31 | 12; 82%HRmax; 2.5; 60 | 7%↓NS | 8%↑NS | 4%↓NS | |
| C, UT, M | 31 | No intervention | 0%↔NS | 7%↑NS | 0%↔NS | |
| Randers | F, UT, M | 31 | 64; 82%HRmax; 1.3; 60 | 0%↔NS | 8%↑NS | 7%↓NS |
| C, UT, M | 32 | No intervention | 2%↑NS | 0%↔NS | 7%↑NS | |
| Randers | F, UT, Mh | 36 | 12; 82%HRmax; 2.2; 60 | 0.1↓NS | 0.0↔NS | 0.4↓*NS† |
| C, UT, Mh | 43 | No intervention | 0.1↑NS | 0.1↓NS | 0.1↑NS | |
| Krustrup | F, UT, Ma | 46 | 24; 85%HRmax; 1.7; 60 | – | 8%↓NS | 9%↓NS |
| DAG, UT, Ma | 47 | DA on CRF | – | 9%↑NS | 9%↑NS | |
| Knoepfli-Lenzin | F, UT, Mmh | 37 | 12; 80%HRmax; 2.4; 60 | 5%↓* | 8%↑NS | 3%↓NS |
| R, UT, Mmh | 36 | 12; 79%HRmax; 2.5; 60 | 2%↓NS | 0%↔NS | 0↔NS | |
| C, UT, Mmh | 38 | No intervention | 4%↓NS | 8%↑NS | 3%↓NS | |
| Schmidt | F, UT, Mt | 51 | 24; 82%HRmax; 1.2; 60 | 5%↓NS | 8%↑NS | 11↑NS |
| C, UT, Mt | 49 | No intervention | 8%↑NS | 9%↑NS | 9%↑NS | |
| De Sousa | F, UT, Mt+Wt | 61 | 12; 83%HRmax; 3; 40; F+D | 0.6↓*† | 0↔NS | 0.4↓*† |
| C, UT, Mt+Wt | 61 | Diet group | 0.4↑NS | 0↔NS | 0.3↑NS |
Changes between pre and post training intervention (unless otherwise stated).
*Significant difference from 0 weeks.
†Significant group difference compared to control.
a, hypertensive participants; C, controls; Chol, cholesterol; CRF; cardiovascular risk factors; DAG, doctor's advice group; F, football; F+D, football+diet group; HDL, high-density lipoprotein; HRmax, maximal heart rate; LDL, low-density lipoprotein; M, men; mh, mildly hypertensive participants; NS, not significant; R, running; t, type 2 diabetics; Total-chol, total plasma cholesterol; UT, untrained; W, women.
Changes in body composition in untrained men as a result of a period of recreational F training compared to R or inactive C
| Study | Activity, target group, gender | Age (years) | Training programme; | Total fat mass (kg) | Total fat percentage (%) | Lean body mass, whole body (kg) | Lean body mass, legs (kg) | Bone mineral density, left and right proximal femur (%) | Bone mineral density, left and right femoral neck (%) | Bone mineral density (legs) (%) | Bone mineral density, trunk (%) | Bone marker –osteocalcin (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Krustrup | F, UT, M | 29 | 12; 82%HRmax; 2.3; 60 | 2.7↓*† | 2.9↓*† | 1.7↑*† | 1.1↑*† | – | – | – | – | – |
| R, UT, M | 31 | 12; 82%HRmax; 2.5; 60 | 1.7↓* | 1.7↓* | 0.6↑NS | 0.6↑NS | – | – | – | – | – | |
| C, UT, M | 31 | No intervention | 0.3↓NS | 0.2↓NS | 0.1↑NS | 0.3↓NS | – | – | – | – | – | |
| Randers | F, UT, M | 31 | 64; 82%HRmax; 1.3; 60 | 3.2↓*† | 3.8↓*† | 2.7↑* | 1.1↑*†‡ | – | – | 2%↑* | – | – |
| C, UT, M | 32 | No intervention | 0.2↓NS | 0.6↓NS | 1.2↑* | 0.2↑NS | – | – | 1%↑NS | – | – | |
| Helge | F, UT, M | 68 | 52; 82%HRmax; 1.7; 45–60 | – | – | – | – | LL:2.4%↑* RL:2.9%↑* | LL:5.4%↑* RL:3.8%↑* | – | – | 46%↑*† |
| S, UT, M | 69 | 52; 8–20RM; 1.9; 45–60 | – | – | – | – | NS | NS | – | – | NS | |
| C, UT, M | 67 | No intervention | – | – | – | – | NS | NS | – | – | NS | |
| Krustrup | F, UT, Ma | 46 | 24; 85%HRmax; 1.7; 60 | 1.9↓NS | 2.2↓NS | 0.2↑NS | 0.1↑NS | – | – | 2.1%↑NS | – | – |
| DAG, UT, Ma | 47 | DA on CRF | 0.9↓NS | 1.0↓NS | 0.2↑NS | 0.0↔NS | – | – | 0.0% NS | – | – | |
| Knoepfli-Lenzin | F, UT, Mmh | 37 | 12; 80%HRmax; 2.4; 60 | 2.0↓* | 2.0↓*† | 0.5↑NS | – | – | – | – | – | – |
| R, UT, Mmh | 36 | 12; 79%HRmax; 2.5; 60 | 1.7↓* | 1.4↓NS | 0.0↔NS | – | – | – | – | – | – | |
| C, UT, Mmh | 38 | No intervention | 0.1↑NS | 0.1↑NS | 0.3↓NS | – | – | – | – | – | – | |
| De Sousa | F, UT, Mt+Wt | 61 | 12; 83%HRmax; 3; 40; F+D | 3.4↓* | 2.4↓NS | 0.2↓NS | – | – | – | – | – | – |
| C, UT, Mt+Wt | 61 | Diet group | 3.7↓* | 2.4↓NS | 1.0↓NS | – | – | – | – | – | – | |
| Andersen | F, UT, Mt | 51 | 24; 83%HRmax; 1.5; 60 | 1.7↓* | 1.5↓* | 0.7↑NS | 0.5↑NS | – | – | NS | – | – |
| C, UT, Mt | 49 | No intervention | 0.1↓NS | 0.2↓NS | 0.8↑NS | 0.5↓* | – | – | NS | – | – | |
| Helge | F, UT, Mh | 36 | 12; 82%HRmax; 2.2; 60 | 1.8↓* | – | 0.9↑* | – | – | – | – | 1%↑* | 27%↑*† |
| C, UT, Mh | 43 | No intervention | NS | – | NS | – | – | – | – | NS | NS | |
| Uth | F, UT, Mp | 67 | 12; 85%HRmax; 2–3; 45–60 | 1.3↓* | 0.9↓* | 0.9↑*† | – | – | – | – | – | – |
| C, UT, Mp | 67 | No intervention | 0.3↓NS | 0.0↔NS | 0.1↑NS | – | – | – | – | – | – |
Changes between pre and post training intervention (unless otherwise stated).
*Significant difference from 0 weeks.
†Significant group difference compared to control.
‡Significant group differences.
a, hypertensive subjects; C, controls; CRF, cardiovascular risk factors; DAG, doctor's advice group; F, football; F+D, football+diet group; h, homeless subjects; HRmax, maximal heart rate; LL, left leg; M, men; mh; mildly hypertensive subjects; NS, not significant; p, prostate cancer patients; R, running; RL, right leg; S, strength training; t, type 2 diabetics; UT, untrained; W, women
Changes in muscle enzymatic activity and capillarisation in untrained men as a result of a period of recreational F training compared to R or inactive C
| Study | Activity, target group, gender | Age (years) | Training intervention; | Capillarisation, cap per fibre (%) | CS activity (%) | HAD activity (%) |
|---|---|---|---|---|---|---|
| Krustrup | F, UT, M | 29 | 12; 82%HRmax; 2.3; 60 | 22%↑† | 14%↑† | 5%↑NS |
| R, UT, M | 31 | 12; 82%HRmax; 2.5; 60 | 16%↑ | 7%↑NS | 5%↑NS | |
| C, UT, M | 31 | No intervention | 5%↑NS | 11%↓NS | 11%↓NS | |
| Randers | F; UT; M | 31 | 64; 82%HRmax; 1.3; 60 | – | 18%↑ | 16%↑NS |
| C; UT; M | 32 | No intervention | – | – | – | |
| Andersen | F, UT, Mt | 51 | 24; 83%HRmax; 1.5; 60 | 7%↑ | 7%↓NS | 5%↓NS |
| C, UT, Mt | 49 | No intervention | 5%↓NS | 9%↑NS | 1%↑NS |
Changes between pre and post training intervention (unless otherwise stated).
†Significant group difference compared to control.
CS, citrate synthase; C, controls; HAD, 3-hydroxyacyl-CoA dehydrogenase; HRmax, maximal heart rate; F, football; M, men; NS, not significant; R, running; t, type 2 diabetics; UT, untrained.
Changes in performance of untrained men as a result of a period of recreational F training compared to R or inactive C
| Study | Activity, target group, gender | Age (years) | Training programme; | Time to exhaustion, max work (s) | Counter-movement jump (%) | Sprint, 30 m (s) | Max leg strength (kg or %) | Yo-Yo | Yo-Yo | Postural balance, flamingo test (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Krustrup | F, UT, M | 29 | 12; 82%HRmax; 2.3; 60 | 102↑* | – | 0.11↑* | 11%↑*†‡ | – | 420↑*†‡ | – |
| R, UT, M | 31 | 12; 82%HRmax; 2.5; 60 | 101↑* | – | 0.01↓NS | 1%↓NS | – | 195↑* | – | |
| C, UT, M | 31 | No intervention | 25↑* | – | – | 2%↑NS | – | 21↑NS | – | |
| Randers | F, UT, M | 31 | 64; 82%HRmax; 1.3; 60 | 98↑* | 5%↑*† | 0.15↑* | – | – | 382↑* | 49%↑* |
| C, UT, M | 32 | No intervention | – | 0%↔NS | – | – | – | – | 27%↑NS | |
| Jakobsen | F, UT, M | 29 | 12; 82%HRmax; 2.3; 60 | – | 1%↓NS | – | 0%↔NS | – | – | 41%↑*† |
| R, UT, M | 31 | 12; 82%HRmax; 2.5; 60 | – | 1%↓NS | – | 2%↓NS | – | – | 38%↑*† | |
| C, UT, M | 31 | No intervention | – | 3%↓NS | – | 0%↔NS | – | – | 11%↑NS | |
| Andersen | F, UT, M | 68 | 16; 84%HRmax; 1.6; 45–60 | 53↑*† | NS | – | – | – | 43%↑*† | – |
| S, UT, M | 69 | 16; 8–20RM; 1.5; 45–60 | 43↓NS | NS | – | – | – | 8%↑NS | – | |
| C, UT, M | 67 | No intervention | 58↓NS | NS | – | – | – | 5%↓NS | – | |
| Krustrup | F, UT, Ma | 46 | 24; 85%HRmax; 1.7; 60 | 79↑NS | – | – | – | – | – | – |
| DAG, UT, Ma | 47 | DAG on CRF | 19↑NS | – | – | – | – | – | – | |
| Knoepfli-Lenzin | F, UT, Mmh | 37 | 12; 80%HRmax; 2.4; 60 | 0.9↑*†§ | – | – | – | – | 144↑* | – |
| R, UT, Mmh | 36 | 12; 79%HRmax; 2.5; 60 | 1.1↑*†§ | – | – | – | – | 168↑*† | – | |
| C, UT, Mmh | 38 | No intervention | 0.0↔NS§ | – | – | – | – | 50↑NS | – | |
| Schmidt | F, UT, Mt. | 51 | 24; 82%HRmax; 1.2; 60 | – | – | – | – | – | 377↑* | – |
| C, UT, Mt | 49 | No intervention | – | – | – | – | – | 52↑NS | – | |
| Helge | F, UT, Mh | 36 | 12; 82%HRmax; 2.2; 60 | – | – | – | – | – | – | 46%↑* |
| C, UT, Mh | 43 | No intervention | – | – | – | – | – | – | 3%↓NS | |
| Uth | F, UT, Mp | 67 | 12; 85%HRmax; 2–3; 45–60 | – | – | – | 8.9↑*† | – | – | – |
| C, UT, Mp | 67 | No intervention | – | – | – | 2.2↑NS | – | – | – | |
| Faude | F, UT, OCh | 11 | 12; 80%HRmax; 4.5; 60 | – | 15%↑* | – | – | – | – | – |
| SP, UT, OCh | 11 | 12; 77%HRmax; 4.5; 60 | – | 14%↑* | – | – | – | – | – | |
| Bendiksen | F+H, UT, Ch | 9 | 6; 76%HRmax; 2; 30 | – | – | – | – | 148↑*† | – | – |
| C, UT, Ch | 9 | Low-intensity activities | – | – | – | – | 106↓NS | – | – |
Changes are between pre and post training intervention (unless otherwise stated).
*Significant difference from 0 weeks.
†Significant group difference compared to control. ‡Significant group differences.
§Maximal velocity (km/h).
¶Yo-Yo IR1 children.
a, hypertensive participants; C, children; C, controls; CRF, cardiovascular risk factors; DAG, doctor's advice group; F, football; F+H, football+hockey; h, homeless participants; HRmax, maximal heart rate; M, men; mh, mildly hypertensive participants; NS, not significant; OC, overweight children; p, prostate cancer patients; R, running; S, strength training; SP, standard physical activity; t, type 2 diabetics; UT, untrained.